搜档网
当前位置:搜档网 › HY-P0125_21847_MCE

HY-P0125_21847_MCE

HY-P0125_21847_MCE
HY-P0125_21847_MCE

Data Sheet

BIOLOGICAL ACTIVITY:

Elamipretide is a cardiolipin peroxidase inhibitor and mitochondria–targeting peptide, Improves Left Ventricular and Mitochondrial Function.

In vitro: Elamipretide significantly increases enzymatic activities of both complexes to near normal levels. long–term therapy with elamipretide reduces ROS formation, attenuated mPTP openings, and significantly decreases the levels of cytosolic cytochrome c and active caspase–3, thus suppressing a major signaling pathway for apoptosis. Elamipretide represents a new class of compounds that can improve the availability of energy to failing heart and reduce the burden of tissue injury caused by excessive ROS production. [1]In vivo: Fourteen dogs with microembolization–induced HF are randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily. Elamipretide has been shown to enhance ATP synthesis in multiple organs, including heart, kidney,neurons, and skeletal muscle. [1]

References:

[1]. Sabbah HN et al. Chronic Therapy With Elamipretide (MTP–131), a Novel Mitochondria–Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2).

Product Name:Elamipretide Cat. No.:HY-P0125CAS No.:

736992-21-5Molecular Formula:C 32H 49N 9O 5Molecular Weight:639.79Target:Others Pathway:Others

Solubility:

DMSO: ≥ 29 mg/mL

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.sodocs.net/doc/ea1491792.html,

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Certificate of Analysis

PHYSICAL AND CHEMICAL PROPERTIES

Molecular Formula:C 32H 49N 9O 5Molecular Weight:639.79Storage:

Powder -20°C 3 years 4°C 2 years In solvent

-80°C 6 months -20°C

1 month

Chemical Structure:

ANALYTICAL DATA

Appearance:

White to off-white (Solid)1

H NMR Spectrum:

Consistent with structure LCMS:Consistent with structure Purity (LCMS):99.53%

Conclusion:

The product has been tested and complies with the given specifications.

Product Name:Elamipretide Cat. No.:HY-P0125CAS No.:736992-21-5Batch No.:21847

Chemical Name:

L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.sodocs.net/doc/ea1491792.html,

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Safety Data Sheet Revision Date:May-24-2017

Print Date:May-24-2017

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifier

Product name :Elamipretide

Catalog No. :HY-P0125

CAS No. :736992-21-5

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses :Laboratory chemicals, manufacture of substances.

1.3 Details of the supplier of the safety data sheet

Company:MedChemExpress USA

Tel:609-228-6898

Fax:609-228-5909

E-mail:sales@https://www.sodocs.net/doc/ea1491792.html,

1.4 Emergency telephone number

Emergency Phone #:609-228-6898

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Not a hazardous substance or mixture.

2.2 GHS Label elements, including precautionary statements

Not a hazardous substance or mixture.

2.3 Other hazards

None.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms:MTP?131; MTP131; MTP 131; RX?31; SS?31

Formula:C32H49N9O5

Molecular Weight:639.79

CAS No. :736992-21-5

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye contact

Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.

Skin contact

Rinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.

Inhalation

Immediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.

Ingestion

Wash out mouth with water; Do NOT induce vomiting; call a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2).

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, dry chemical, foam, and carbon dioxide fire extinguisher.

5.2 Special hazards arising from the substance or mixture

During combustion, may emit irritant fumes.

5.3 Advice for firefighters

Wear self-contained breathing apparatus and protective clothing.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.

Refer to protective measures listed in sections 8.

6.2 Environmental precautions

Try to prevent further leakage or spillage. Keep the product away from drains or water courses.

6.3 Methods and materials for containment and cleaning up

Absorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.

Recommended storage temperature:Powder-20°C 3 years

4°C 2 years

In solvent-80°C 6 months

-20°C 1 month

Shipping at room temperature if less than 2 weeks.

7.3 Specific end use(s)

No data available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

This product contains no substances with occupational exposure limit values.

8.2 Exposure controls

Engineering controls

Ensure adequate ventilation. Provide accessible safety shower and eye wash station.

Personal protective equipment

Eye protection Safety goggles with side-shields.

Hand protection Protective gloves.

Skin and body protection Impervious clothing.

Respiratory protection Suitable respirator.

Environmental exposure controls Keep the product away from drains, water courses or the soil. Clean

spillages in a safe way as soon as possible.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance White to off-white (Solid)

Odor No data available

Odor threshold No data available

pH No data available

Melting/freezing point No data available

Boiling point/range No data available

Flash point No data available

Evaporation rate No data available

Flammability (solid, gas)No data available

Upper/lower flammability or explosive limits No data available

Vapor pressure No data available

Vapor density No data available

Relative density No data available

Water Solubility No data available

Partition coefficient No data available

Auto-ignition temperature No data available

Decomposition temperature No data available

Viscosity No data available

Explosive properties No data available

Oxidizing properties No data available

9.2 Other safety information

No data available.

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available.

10.4 Conditions to avoid

No data available.

10.5 Incompatible materials

Strong acids/alkalis, strong oxidising/reducing agents.

10.6 Hazardous decomposition products

Under fire conditions, may decompose and emit toxic fumes.

Other decomposition products - no data available.

11.TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

Classified based on available data. For more details, see section 2

Skin corrosion/irritation

Classified based on available data. For more details, see section 2

Serious eye damage/irritation

Classified based on available data. For more details, see section 2

Respiratory or skin sensitization

Classified based on available data. For more details, see section 2

Germ cell mutagenicity

Classified based on available data. For more details, see section 2

Carcinogenicity

IARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.

NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.

OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.

Reproductive toxicity

Classified based on available data. For more details, see section 2

Specific target organ toxicity - single exposure

Classified based on available data. For more details, see section 2

Specific target organ toxicity - repeated exposure

Classified based on available data. For more details, see section 2

Aspiration hazard

Classified based on available data. For more details, see section 2

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No data available.

12.2 Persistence and degradability

No data available.

12.3 Bioaccumlative potential

No data available.

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.

12.6 Other adverse effects

No data available.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Dispose substance in accordance with prevailing country, federal, state and local regulations.

Contaminated packaging

Conduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.

14. TRANSPORT INFORMATION

DOT (US)

This substance is considered to be non-hazardous for transport.

IMDG

This substance is considered to be non-hazardous for transport.

IATA

This substance is considered to be non-hazardous for transport.

15. REGULATORY INFORMATION

SARA 302 Components:

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards:

No SARA Hazards.

Massachusetts Right To Know Components:

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components:

No components are subject to the Pennsylvania Right to Know Act.

New Jersey Right To Know Components:

No components are subject to the New Jersey Right to Know Act.

California Prop. 65 Components:

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.

16. OTHER INFORMATION

Copyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.sodocs.net/doc/ea1491792.html,

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

ppm (t1)

0.0

1.02.03.04.05.06.07.08.09.010.011.012.08.939

8.545

8.5238.3118.2927.9987.990

7.8457.8257.7067.7047.5137.487

7.2617.2457.1226.323

4.7794.762

4.4504.438

4.215

3.8163.8043.8023.4252.9962.985

2.8372.7102.5092.5042.5002.4962.491

2.176

1.5081.5051.4921.4911.4861.473

1.2311.2271.2231.2211.2191.21712040004

1.019

1.008

0.889

0.937

0.952

0.833

1.799

1.077

2.8992.02010.179

6.000

1.162

3.073

8.075

7.252

Date:

28 Sep 2016

Document's Title:

&DWDORJ 1R +< 3 %DWFK Spectrum Title:

HY_BIZ2016-927-WJ6-DMSO

Frequency (MHz):(f1) 399.738

Original Points Count:(f1) 65536

Actual Points Count:(f1) 65536

Acquisition Time (sec):(f1) 8.1789

Spectral Width (ppm):(f1) 20.045 Pulse Program:Unknown

Sample ID: BIZ2016-927-WJ6, Catalog No: HY-P0125 Batch#21847. DMSO

NH

O

NH 2

HN

NH 2

O

H N

OH

O NH 2

O Chemical Formula:C 32H 49N 9O 5

Exact Mass:639.39

File D:\CHEM32\1\DATA\BIZ\BIZ2016-927-WJ6.D Tgt Mass (EZX): 639.00 Injection Date : 27 Sep 16 1:25 pm +0800 Seq. Line : 0 Sample Name : BIZ2016-927-WJ6 Location : P1-F-01 Acq. Operator : KFF(LCMS-02) Inj : 1 Spec. Reported : MS Integration Inj Volume : 1 ul Acq. Method : D:\Chem32\1\METHODS\1-POS-3MIN.M

Analysis Method : D:\CHEM32\1\METHODS\1-POS-3MIN-PROSRSS.M

Catalog No : HY-P0125 Batch#21847 Easy-Access Method: '1-POS-3MIN' 639.00 Method Info : Mobile Phase: A: water(0.01%TFA) B:ACN(0.01%TFA) Gradient: 5% to 95%B within 1.3 min Flow Rate :1.8ml/min

Column :SunFire C18, 4.6*50mm,3.5um A-RP-186

Oven Temperature : 45C

min*

0.51

1.52

2.5mAU 0

100200300400*DAD1 B, Sig=214,4 Ref=off 1.081

1.368

min

0.51 1.5

2

2.5

20000

400006000080000 MSD1 TIC, MS File ES-API, Pos, Scan, Frag: 70

1.070

min

0.5

1

1.5

2

2.5

2000

4000600080001000012000 Ion 640, MSD1 640,Target Mass 639 +H Positive, EIC=639.7:640.7

1.069

Integration Results for DAD1 B, Sig=214,4 Ref=off

RetTim Width Area Height Area% MS(+)|-------|--------|--------------|--------------|--------|------| 1.08 0.02 572.21 534.12 99.53 321 1.37 0.04 2.68 1.01 0.47 233

Ret. Time: 1.07 <<<< POSITIVE SPECTRA >>>>

m/z

200

300

400

500

600

700

800

900

2000

40006000800010000

120001400016000 ES-API Positive

641.5 640.4

320.8

相关主题